The CRISPR Atlas

Treatments

Named gene-editing and gene-therapy medicines, from approved products to programmes that have been discontinued.

15 treatments in the Atlas. Grouped by the stage each programme has actually reached. Only approved products are available to patients outside a trial; “in trials” never means a treatment is proven.

15 shown

Approved3

Casgevy (exagamglogene autotemcel) Vertex Pharmaceuticals / CRISPR Therapeutics Approved 2023 · $2.2 million (US list price) CRISPR-Cas9 Lyfgenia (lovotibeglogene autotemcel) bluebird bio Approved 2023 · $3.1 million (US list price) Lentiviral gene addition Zynteglo (betibeglogene autotemcel) bluebird bio Approved 2022 · $2.8 million (US list price) Lentiviral gene addition

Phase III4

Nexiguran ziclumeran (nex-z) Intellia Therapeutics CRISPR-Cas9 Lonvoguran ziclumeran (lonvo-z) Intellia Therapeutics CRISPR-Cas9 Risto-cel (BEAM-101) Beam Therapeutics Base editing BEAM-302 Beam Therapeutics Base editing

Phase II1

VERVE-102 Eli Lilly Base editing

Phase I4

PM359 Prime Medicine Prime editing CTX112 CRISPR Therapeutics CRISPR-Cas9 CB-010 Caribou Biosciences CRISPR-Cas12a Hypoimmune islet cell therapy Sana Biotechnology CRISPR-Cas9

Preclinical1

EDIT-401 Editas Medicine CRISPR-Cas9

Not proceeding1

EDIT-101 (Brilliance) Editas Medicine CRISPR-Cas9

Other status1

Bespoke base editor for CPS1 deficiency (the KJ Muldoon case) Academic — CHOP and Penn Completed

How to read this board Only the first column has been authorised by a regulator for use in patients. Everything to the right of it is research: being in Phase III is not evidence that a treatment works, and most programmes at every stage never reach approval. Stages reflect the most advanced study we hold a record for.